Does Metformin Block the Health Benefits of Exercise? Podcast with Ben Miller

Physical exercise is one of the best anti-aging interventions at our disposal. Indeed, it may be the best. You have no doubt heard this before, but you probably don’t realize just how powerful it is. 

Epidemiology has provided some particularly compelling evidence. Research has shown, for instance, that cardiorespiratory fitness is one of the strongest predictive factors for survival into old age. In one study, men with the lowest exercise capacity were 4.5 times as likely to die within the follow-up time period, compared to those with the highest exercise capacity. And in men aged 75, exercise capacity was the most powerful predictor of survival to age 90, exceeding that of conventional risk factors like smoking, high blood pressure, total cholesterol, and obesity.

Exercise capacity is a more powerful predictor of mortality among men than other established risk factors for cardiovascular disease.

So if you want to live a long life – and more importantly, a healthy and productive one – exercise is a key tool to make that happen. But in order to further push the limits of lifespan and healthspan, it is thought that pharmaceutical drugs to target the aging process may be needed. 

 

METFORMIN

One well-elucidated candidate is the anti-hyperglycemic drug metformin. Metformin was discovered in 1922, and was first introduced as a medication in Europe in 1957. It is now the most widely prescribed medication to treat type 2 diabetes in the world, and the 4th most prescribed medication in the United States, with more than 81 million total prescriptions in 2016. 

While it has classically been used to help control blood sugar in people diagnosed with diabetes, it has recently emerged as a possible anti-aging drug, as we have discussed previously. This is largely because systematic reviews of the literature have found that patients with diabetes who take metformin have substantially reduced risk of cardiovascular disease, cancer, and all-cause mortality – not just compared to other people with diabetes, but even in comparison to non-diabetics! It appears to extend lifespan and augment health independent of its effect on diabetes. 

You can imagine how healthy people might think that taking a pill like metformin could prevent the onset of metabolic derangement and other age-related illnesses on this basis – and some folks out there are already doing just that! But several researchers have wondered if metformin might come with some serious downsides, particularly with respect to exercise. 

This is because we know that aerobic exercise boosts the capacity for energy production through mitochondrial biogenesis and mitochondrial respiration. This is vital to its known benefits for insulin sensitivity and cardiorespiratory fitness. Metformin, in contrast, actually works by inhibiting mitochondrial respiration. So these two interventions, in theory, are operating at biochemical cross-purposes. Is it possible that taking metformin is simultaneously subverting the anti-aging benefits of physical exercise – thus undermining your original goal of extending lifespan and healthspan?

You would probably think that the best way to test this would be to compare the effects of exercise in people taking metformin compared to controls, and see if there is a difference when the two are combined, right? That’s exactly what researchers have done at last, and the results are eye-opening.

And that brings me to our guest.

 

GUEST

On this episode of humanOS Radio, we welcome Ben Miller to the show. Ben is a principal investigator in the aging and metabolism research program at the Oklahoma Medical Research Foundation. His lab studies the interaction of mitochondrial energetics, protein turnover, and stress resistance, with the overarching goal of slowing the aging process and extending the period of life in which we are free of disease (healthspan).

Let me quickly spoil some of the study findings so you can see why this matters – then you should check out the interview to learn more.

In the study, Miller and his team recruited 53 participants and then randomly assigned them to consume either placebo or metformin. During the 12-week study period, all subjects also completed a supervised aerobic exercise program. They visited the lab three times per week to perform aerobic activity (45 minutes per session). The researchers measured VO2max, BMI, and insulin sensitivity. They also took muscle biopsies of the subjects’ quadriceps.

This exercise regimen elicited measurable improvements in blood sugar control, insulin sensitivity, and aerobic fitness for the volunteers. As you would obviously expect. But when the groups were compared, some meaningful and troubling differences emerged.

For one thing, subjects taking metformin did not improve their endurance nearly as much as their counterparts in the placebo group. Metformin blunted the increase in VO2max by about 50%. Secondly, metformin appeared to inhibit the rise in whole-body insulin sensitivity associated with exercise in many of the participants. 

So it looks like metformin was, in effect, blocking some of the awesome health benefits that are normally gleaned from physical activity. But why?

The muscle biopsies offered a window into what was going on here. Mitochondrial respiration had risen by around 25% in the placebo group. In contrast, there was little to no improvement in mitochondrial respiration in the muscle cells of the group taking metformin. Decidedly not great, if you are an athlete – or even if you are just someone who wants to reap the aforementioned benefits of aerobic fitness throughout the lifespan.

This is just one study, of course (although some other past experiments have suggested that metformin may have antagonistic effects on health benefits induced by exercise). But it raises some important questions about using pharmaceutical drugs prophylactically in healthy individuals, and certainly about the use of metformin specifically. Should you use metformin to prevent aging, if you are a physically active person that is free of chronic disease? Or are you potentially doing more harm than good? These are complicated questions, that are frankly not easy to answer. Check out the interview below, to learn more!

 

 

LISTEN HERE

On Soundcloud, iTunes, Google Play, Stitcher, and YouTube

 

YOUTUBE

SUPPORT

Have you considered becoming a Pro member of humanOS.me? It costs just $9.99 per month, and when you go Pro, you get access to all our courses, tools, recipes, and workouts. Pro members also support our work on blogs and podcasts, so thanks!

 

LEAVE A REVIEW

If you think other people would benefit from listening to this show, you can help us spread the word by leaving a review at iTunes. Positive reviews really help raise the profile of our show!

 

TRANSCRIPT

Ben Miller:	00:06	We saw that the muscle mitochondria, actually a lot of the training-induced improvements that you would expect and we saw in the placebo group were blunted in the metformin group, and I think that’s the primary finding of this study.
Speaker 2:	00:25	humanOS. Learn, master, achieve.
Dan Pardi:	00:32	Hello everybody, I’d like to welcome Ben Miller to humanOS Radio. Ben is the principal investigator in the aging and metabolism research program at the Oklahoma Medical Research Foundation. His lab studies the interaction of mitochondrial energetics, protein turnover, and stress resistance with the overarching goal of slowing the aging process and extending health span. We’ve addressed aspects of the aging process many times before on the show. People are living longer than ever before, but as we get older we become more susceptible to chronic degenerative disease, which gradually robs us of our independence and reduces the quality of our lives. So we may live a long life, but much of those years are spent relatively unhealthy. So we don’t really want to live longer without good health. We want to increase our health span as well.
Dan Pardi:	01:23	This has given rise to interest in the pharmaceutical industry and with pharmaceutical drugs that could target the aging process itself, not just chronic disease. One potential candidate is the antihyperglycemic drug, metformin. Metformin has been around for a long time. It was discovered in 1922 and first introduced as a medication in Europe in 1927. It is now the most widely prescribed medication to treat type two diabetes in the world and the fourth most prescribed medication in the United States, with more than 81 million total prescriptions in 2016. Reviews of the literature has shown that people with diabetes who take metformin are at reduced risk for cardiovascular disease, cancer and all-cause mortality. It appears to extend lifespan and augment health independent of its effects on diabetes. Sounds pretty good, right? So does this mean that everyone should start taking it? Maybe not.
Dan Pardi:	02:16	It has been shown for some time that metformin may actually interfere with the health benefits associated with aerobic exercise, particularly in insulin sensitivity and cardiorespiratory fitness. A recent study from Ben and his team found this to be the case and also sheds light on some of the reasons why this antagonism occurs. So I am delighted that he is here with me today. Ben, welcome to humanOS radio.
Ben Miller:	02:39	Thank you. I very much appreciate the invite.
Dan Pardi:	02:41	So before we dive into the study itself, let’s talk about your background. How did you become interested in biogerontology?
Ben Miller:	02:47	Actually, I was not trained in that area. I was trained in metabolism and became an expert in the use of [inaudible 00:02:54] isotopes, during my PhD. I went to do a postdoc in Copenhagen, Denmark at a famous muscle research center there and during that time I actually started to become interested in the aging process and the loss of muscle mass with time. As I moved forward in my career and then subsequently moved to a new institute, I really started to focus in on mitochondria and aspects of protein turnover in the making the mitochondria as it pertains to maintaining muscle mass with age.
Ben Miller:	03:23	During that time, I found aging to be a really fascinating question and I suppose as I’ve gone further, I’ve gotten more and more into the basic biology of aging. So even though muscle continues to be my primary tissue of interest, all these other tissues and what is basically driving the aging process has become more and more a part of the research process. So we tend to look at a variety of organs not just muscle with a little bit of an increasing focus on the brain, although we’re still rather novice in that area. It’s really interesting to me what fundamentally is going wrong to cause this deterioration over time and how we might slow that process.
Ben Miller:	04:02	Most people know that aerobic exercise and cardiorespiratory fitness prevent chronic disease, but they might not know much about the underlying chemistry. Talk about how activation of AMPK, the enzyme, contributes to the health benefits associated with exercise training.
Ben Miller:	04:17	So AMPK is basically this energy sensor of the cell. It detects when your ratios of ADP to ATP change and then put them in motion processes to correct this energetic stress that you have at a particular time. With exercise, obviously with the robotic exercise especially, you have this activation of AMPK during the exercise bout. The temporal response actually is not completely well-defined as far as when you have activation, when you restore that to normal homeostatic state around the bout of exercise but it’s pretty safe to say that the aerobic exercise itself stimulates AMPK. Once you stimulate AMPK, you have a whole host of downstream effectors as you can imagine, to correct this energetic deficits, which winds up changing the metabolic program at that period of time and changes what the cell does to deal with energetic constraints. Your cell can’t do everything at once, so these basic processes costs energy.
Ben Miller:	05:18	So if you think about making things like protein, that’s energetically costly and in reality it’s one of the most energetically costly things your cell does. If you think about the pumps and you think about everything else that’s going on in the cell, while at the same time, say in the muscle, having to produce energy to activate this crossbridge cycling that allows you to perform contractions. So it’s a delicate balance, it’s a complicated balance and it’s something that’s not completely figured out yet.
Dan Pardi:	05:45	What does the activation of AMPK lead to in terms of some of the cellular responses that we see?
Ben Miller:	05:51	Acutely, one thing for sure, it will go through the mTOR pathway, which is downstream of it and turn off the making of proteins. So like I said, making proteins is energetically costly, so that is something you might not need to do while you’re exercising and that process gets shut down. So it makes those decisions to be able to do what you need to do at that period of time. Again, I’ll say that the temporal response to this is very complicated because we know that something like aerobic exercise will then lead to adaptations to better respond to that this is a stress resistance or you impose a stress on a cell and then later on it makes adjustments to be able to respond to that stress better in the future. So as soon as acutely that AMPK activation may be down, but if you think about the fact that the cell then needs to adapt to that stress, you will reverse that when you have energy available again, to be able to make the adjustments that you need to to adjust to that stress.
Dan Pardi:	06:51	So we know that exercise will elicit that. Metformin appears to activate AMPK as well. How does it work? How is metformin similar to and different from exercise induced AMPK increases?
Ben Miller:	07:04	Believe it or not, how metformin works is really one of the million dollar questions right now. So it’s not exactly known what the mechanism of metformin is. We do have a sense, although the data are not conclusive that it might be a complex I inhibitor of the complex I of the electron transport chain of mitochondria. So if it’s a complex I inhibitor, that might create an energetic stress that activates AMPK. So we know that metformin is an AMPK activator, although we don’t know exactly how it is an AMPK activator.
Dan Pardi:	07:36	Let’s do a primer on the electron transport chain. What is the purpose of this electron transport chain? Why is it activated? What is its function?
Ben Miller:	07:43	So this is the way that your body produces energy or your cells produce energy. They take substrates in the form of glucose and fatty acid, and those substrates are made into these reducing equivalents that are than used in a series of redox equations through the electron transport chain. So you go from a gradually increasing state of oxidation and reduction in order to harness that energy to pump hydrogens across the membrane and then at the end of that chain, you let that hydrogen come back through a complex in order to couple the formation of ADP to an inorganic phosphate to make ATP. If you think about it, there’s two analogies here. The engine of a car that takes gasoline, combusts it to make it into usable energy. That’s sort of what your mitochondria are doing, using your nutrients as the fuel source. You can also think about it as pumping these hydrogens and building up a potential energy like you would in a dam and then releasing that dam and coupling the energy to the formation of usable energy for the cell.
Dan Pardi:	08:45	Even though we’re not exactly sure how it works, it might be working at complex I of the electron transport chain to make, interestingly, that process less efficient. It’s not trying to help the electron transport chain work better, it’s actually interfering with it. Correct?
Ben Miller:	08:58	Yeah, it is interfering with it a bit and it’s thought that that occurred. Although there are data that shows that it may be the case and it may not be the case and that’s one of the parts that haven’t completely been worked out yet. If it does inhibit that process, then yes, that is energetic stress saying the mitochondria are not working as well as they should be, or not producing the energy in a way they should be and that might trigger an adaptation. Another thing to keep in mind is that metformin is transported very well into the liver and some of the primary effects as a glucose-lowering drug is thought to be mediated through the liver and to control or inhibit hepatic glucose output, to control the level of glucose in the blood.
Ben Miller:	09:42	So muscle where we looked in this particular project, is not thought to be a primary site of metformin action, although there are many of these other tissues besides the liver that will take up metformin and have effects there as well.
Dan Pardi:	09:56	We see that exercise is doing a lot of the same things as metformin. So you might think that combining metformin and exercise might have added, or even synergistic facts but research has failed to show this. What is previous research shown when metformin and exercise were used together?
Ben Miller:	10:12	Most of the previous research that led to this was really focused on the cardiorespiratory effects of a combination of metformin and exercise, aerobic exercise. The major studies done prior to ours were able to show that metformin, sometimes blunts increase in VO2 max, your measure of cardiorespiratory fitness, when taken in combination with the aerobic exercise training. That was shown both acutely and over exercise training program.
Dan Pardi:	10:41	Right, that’s interesting. Cardiorespiratory fitness is not just something that athletes care about, but it is something that correlates very strongly with longevity and health into the future. So something that would interfere with that would be problematic. That’s what we had seen previously, that there was this interference with metformin on cardiorespiratory fitness. What was your hypothesis and what was the protocol for this research?
Ben Miller:	11:04	What we wanted to do to extend the previous findings, is to look into the skeletal muscle and to look into the mitochondria of the skeletal muscle to see if some of this blunting of these positive effects of aerobic exercise training were happening at the muscle. So we enrolled a number of subjects who were at risk for type two diabetes, so nobody in our study had type two diabetes, but they had at least one risk factor. For many of our subjects, that was just a family history. Once they were enrolled, we underwent a series of tests including measuring cardiorespiratory fitness and taking a muscle biopsy from which we took muscle fibers and looked at the function of the mitochondria in a specialized instrument to look at mitochondrial function. We also did a measure of insulin sensitivity.
Ben Miller:	11:49	They then underwent 12 weeks of exercise training program. They were randomized into a placebo or metformin group. They were able to self-select mostly their exercise training, whether that be an elliptical, biking, or running and we’d gradually progress them through a 12 week training program that are pretty standard exercise training programs. Unintentionally, we got a variety of cardiorespiratory fitness of the people enrolled in the subject. So we had subjects that were somewhat active, then we had subjects that were very close to being diabetic. This wound up being a strength later in the study, although at the time we didn’t realize that.
Ben Miller:	12:26	So we enrolled men and women. On average they were about 62 to 63 years old, so they were a little bit older and at the end of the study we repeated those baseline measurements. What we saw that was quite striking, is that we reproduced that blunting of cardiorespiratory improvement with exercise training that other studies had shown before and we saw that the muscle mitochondria, actually a lot of the training-induced improvements that you would expect and we saw in the placebo group were blunted in the metformin group. I think that’s the primary finding of the study.
Ben Miller:	13:02	What we also saw though, was that the improvements in insulin sensitivity were also blunted. Not only were they blunted, but there was a huge variability in responsiveness. So although the subjects that were on placebo, by and large all of them improved with the exercise training program as far as insulin sensitivity, it was almost about 50/50 from the subjects that were on metformin that improved or did not improve.
Dan Pardi:	13:29	That’s interesting. Were you able to do a subgroup analysis of the responders and the non-responders to mitochondria with insulin sensitivity?
Ben Miller:	13:37	So in the paper we did not, but going back and looking at the data, we started to look at what were the characteristics of those subjects that responded well and did not respond well? Those findings have led to a future study which we’re going to start in the next two months or so, that directly test some of these factors that we think might impact whether people are responders or non-responders to the metformin treatment.
Dan Pardi:	14:05	When was the metformin taken relative to when the exercise occurred? Was it taken at the same time every day, and what was the dose?
Ben Miller:	14:12	We used a clinical dose of metformin, which is about 1,500 milligrams to 2,000 milligrams per day. We were targeting 2,000 milligrams, but one of the common side effects of metformin is gastric distress, so in some subjects we had to back it down to 1,500 milligrams per day. The dose is split between the morning and the evening and that was the same every day, but we did allow the subjects to exercise based on when it was convenient for them.
Dan Pardi:	14:39	So that exercise was not standardized at a certain time? This could have happened to any time during the day, the participants chose when to do it?
Ben Miller:	14:47	Right, but chances are by the schedule that most of them would have been exercise the morning and the evening dose.
Dan Pardi:	14:53	Do you take metformin on an empty stomach? How is it usually dosed?
Ben Miller:	14:56	They actually encourage people not to take it on an empty stomach since it does have some gastric distress with it.
Dan Pardi:	15:02	Okay. There wasn’t really variability in terms of the cardiorespiratory response. Metformin inhibited exercise-induced improvements in cardiorespiratory fitness, but in terms of insulin sensitivity, that’s where you see this dichotomous response. Some people had improved insulin sensitivity and some people did not. For those who had improve insulin sensitivity, how comparable was that improvement to those in the placebo group?
Ben Miller:	15:27	So if you look at the extremes of the placebo and the metformin, you will see subjects that had equal improvements in insulin sensitivity. You do not see the spread and the variability of responsiveness in the placebo group that you’ve see in the metformin group.
Dan Pardi:	15:43	Were you able to assess skeletal muscle mitochondrial respiration and how did you do that and what did you find?
Ben Miller:	15:48	Yeah, so that was one of our primary outcomes. To do these procedures, you use a muscle biopsy, you isolate out some of the muscle fibers from that muscle biopsy and basically you use detergent to poke some holes into the muscle bundle. What that allows for is for you to then introduce substrates and inhibitors into this isolated prep. So this prep goes into an instrument that’s designed to measure oxygen consumption, these are obviously very sensitive instruments. You have a known amount of oxygen in this chamber and as that oxygen declines, you can measure rate of respiration. So the rate of which the mitochondria in these muscle fibers or using oxygen.
Ben Miller:	16:31	Then you go through a series of steps where you can titrate in different doses of say, I want to look at just the function of complex I or complex II, you can control that by adding substrates and inhibitors to the chamber. So you can sort of tease out where you might have positive or negative effects in the mitochondria. Again, the advantages of the method that we used as you leave the mitochondria intact in this muscle prep. So they’re keeping their shape, they’re not being isolated out. There’s advantages and disadvantages to both approaches of isolating mitochondria or leaving them intact, but for our purposes, we preferred to keep them intact.
Dan Pardi:	17:09	You were able to put into this medium of variety of different substrates, depending on the type of the substrate news, you can assess different aspects of mitochondrial function. Is that correct?
Ben Miller:	17:19	Yes, that’s correct.
Dan Pardi:	17:20	Tell the audience how you’re then assessing what part of the mitochondrial electron transport chain is activated and challenged.
Ben Miller:	17:27	I mentioned the fact that you have these redox equations in the mitochondria, and where that energy comes from is passing an electron. So if you pass electrons through the complexes you can assess that by itself or you can assess the mitochondria’s ability then to couple that to ATP production.
Ben Miller:	17:45	Another thing is that when you do these experiments you typically all these energy substrates and oxygen and everything else in what’s considered saturating doses. You don’t want any of those things to be limited, so they look at the maximum function of the mitochondria. What we did in this experiment that we think is very important and we’ve adapted in the lab, is that we also do experiments that the mitochondria aren’t running at full [inaudible 00:18:13]. We titrate in ADP to make ATP, but we titrate that in that sub-max doses so that we can look at how well the mitochondria are working under conditions that are more like what it would see in the muscle. I would say under those conditions is where we saw the most striking effects.
Ben Miller:	18:31	We saw an increase in the ability to consume oxygen at a given ADP concentration, as we went through this gradually increasing concentrations of ADP. We saw a very nice improvement in the placebo group post-exercise, as we would expect. In the metformin treated group, that’s where we saw a complete blunting of the positive effect that we saw with the placebo group.
Dan Pardi:	18:56	So these were samples that were taken out of a leg muscle in the participants. And you had before and after samples so you could see the difference over time?
Ben Miller:	19:05	Correct. We do the measurements as soon as we get the muscle because it has to be done on fresh tissue. We’d compare their responses after the training bout to the responses that we got before the training. Program, I should say.
Dan Pardi:	19:18	As you’d expect with exercise training, a process by which these mitochondria make energy becomes enhanced, an increase in the number of mitochondria, efficiency per mitochondria.
Ben Miller:	19:30	These experiments were testing the combined effect of both mitochondrial content and mitochondrial function, so how well the mitochondria work and whether there’s an increase in the mitochondria total. You can tease apart those two factors. We did not do that so much in this study, but it is something that’s possible to do.
Dan Pardi:	19:51	It would have been interesting to see a group taking metformin without exercise. If you take a group of non-exercise people and you give them metformin without exercise, is there actually an improvement in a repository capacity of the mitochondria? That’s what this is coming down to, for me. There might be a benefit of taking metformin in a sedentary population. It’s not quite as good as exercise, but it’s better than being sedentary.
Ben Miller:	20:14	Right. Something that we’re moving towards now is directly testing that kind of question because you’re left with two unknowns in this study. So is this a blunting that we only see in the face of an exercise training program, or is it have to do with the population that you’re looking at?
Dan Pardi:	20:33	You also measured a few other things. Telomere length, you want to tell us quickly about what you saw there?
Ben Miller:	20:38	The telomere length was interesting, although maybe not directly related to metformin. Telomeres as you know, are these markers that decrease in length over time in that could or could not be tied to the aging process. They tend to be a sensitive marker disease if you’re looking at them the right way. In our study, although we did not see an effect of metformin, what was interesting is the telomere length would increased post-exercise training. To say that a telomere increases in length is actually kind of an interesting observation and it turns out this has been repeated in other studies. I shouldn’t say repeated because we repeated what others have found, that exercise can increase the lengths of telomeres. We don’t really think of telomeres as just shortening and maybe blunting the speed at which they’re shortening, but to actually have an increase is something that’s interesting and maybe I don’t have a direct answer for right now.
Dan Pardi:	21:33	Was there any difference between metformin and exercise?
Ben Miller:	21:35	No, so that was just … The effect of exercises was all we saw in that outcome and it was equal between the two.
Dan Pardi:	21:42	What are some studies that you’re looking to do next in order to advance our understanding further?
Ben Miller:	21:47	One thing I want to comment on is that this study was with aerobic exercise training. There’s a study that recently finished up called the masters trial, where they did metformin and resistance training. So metformin is thought to have some anti-inflammatory effects and the thinking these researchers had was that if you blunt some of this inflammation with metformin in older individuals, you’d have a greater response to the strength training.
Ben Miller:	22:15	So for some reason in that study as well, metformin blunted the positive effects of strength training. So those data are not published yet. I’ve talked to the investigator, the PI on that project several times, and because we’ve saw similar things. So it’s interesting that it was the same with aerobic and strength training.
Ben Miller:	22:34	Where does this lead us next? It’s exactly is to answer some of the questions you brought up. So what is happening when you don’t have aerobic exercise involved in the process? So your normal everyday population that may not be exercising or physically active. That’s a question of interest to us. Then within that population, who are the people that do well with this treatment and who are those that might not do as well? The reason that’s important is because the concept of health span that we’ve been focused on, is idea of prolonging the period spent free of disease. So if we want to have a treatment that prolongs health span, that by definition has to occur before the onset of disease. That means you would be providing a pill to someone that doesn’t have disease yet.
Ben Miller:	23:22	So the rationale for using metformin, or the positive data that has been generated for metformin has mostly been done in people with type two diabetes and it has very positive effects in people with type two diabetes. But if you look at something like the Diabetes Prevention Program, that looks at the progression to diabetes, so these were people that were pre-diabetic and not sick yet, the subjects that were the most healthy in that study were the ones that had the least benefit.
Ben Miller:	23:51	We need to start understanding better in the people that are already healthy, does this have a benefit at all? It’s one thing to say that it doesn’t have a benefit, but it’s another thing to say that it might have detrimental effects. I think that’s what we want to understand more.
Dan Pardi:	24:07	What is the half life of metformin and is it possible that timing could be a factor in its effect? So you could imagine taking metformin just on sedentary days, or in the evening to augment the benefits associated with the fasting period. That is not a very clean idea for people, I think it’s best for people to just say take this at the same time every single day versus having to then judge how physically active you are but I wonder if that is an area where an informed person could be managing this around what else they’re doing in their life?
Ben Miller:	24:38	The half-life on mitochondria is very short and I should be able to give you the exact hours, but I can’t. But it is short-acting and so that does leave open that possibility. But I’ll tell you that in our study we took our muscle biopsies 36 hours after the last dose of metformin, and 48 hours after the last bout of exercise and we did that for a very good reason. We did that because we didn’t want to look at the acute effect of a dose of metformin. So obviously there are some longterm impacts of taking metformin that extend beyond just that acute period in which the medication is in the system.
Dan Pardi:	25:13	Could dose be a factor? Is it possible that healthy people seeking the anti-aging effects could use a lower dose, thus minimizing the drawbacks but still getting some of the benefits? If you don’t have diabetes, could you take a sub-diabetic dose and get a different effect?
Ben Miller:	25:28	I think that’s a really good question and something that we’ve considered when we were thinking about what direction to go next with this research. The dosing and taking lower doses of metformin is the direction we haven’t gone, but I definitely think that’s a question that remains to be answered yet. Could you have positive benefits in those that are not diabetic by lowering the dose and having the subacute effects that are beneficial over time?
Dan Pardi:	25:53	We know that lifestyle modification, so doing 150 minutes of moderate intensity exercise per week, prevents the progression from prediabetes to type two diabetes by 58%, where metformin has shown to prevent that progression by 31%, so both are eliciting a positive effect here. I wonder if we could identify a level if you say, “Well, I’m not entirely sedentary. I’m not necessarily training hard, but I do walk every week and I’m doing some degree of physical activity,” and that you compare that with people who are actually able to maintain the national guidelines for exercise recommendations.
Dan Pardi:	26:31	Can we figure out an algorithm where if assess somebody’s physical activity level then you could say, “Okay, this is a person where metformin will be additive and if you are currently maintaining a level above this, then you’re using the effects of metformin even more so, so stick on your regimen and so you can’t do that any longer.”
Ben Miller:	26:46	That’s an interesting direction to go and one that I hoped we would get to at some point. Right now when we think about, okay, should we prescribe metformin for slowed aging, there is not that sort of nuance in it right now. All it is, is that okay, well we need to put people on metformin and see if it slows the aging process. I’m all for finding the right treatment to slow the aging process. A lot of research with exercise training, and I know exercise training works and I’m a huge advocate for it primarily, but the reality is that we can’t get everybody to exercise and we do have to find some alternative approaches to it to slow this aging process. That might come in pill form and it may be metformin, but I don’t think we’re at a point right now where we understand enough that we can say that “Yes, this is the slowed aging treatment that we should use first.”
Dan Pardi:	27:42	It sounds like metformin’s effects on the complex I and the electron transport chain in the mitochondria, it could have an effect there, although it might not. Is that exclusive to metformin or do we know other molecules that also will interfere with aspects of the electron transport chain, making them less efficient and therefore possibly inducing being an exercise mimetic?
Ben Miller:	28:05	I’d hesitate to say exercise mimetic for anything, I guess because we know the wide range of effects that exercise has besides just on the electron transport chain. It sounds nice, I just don’t think it’s possible to capture that in a pill, but there are drugs that have effects at the mitochondria. There’s a whole series of drugs that are targeted antioxidants to the mitochondria, or they upregulate systems in the mitochondria to defend itself and there’s a whole series of those types of drugs out there. I think what is common that we see in some of these drugs, is you’re activating pathways that are stress responsive. We know that low dose stress is a very positive thing because if the cell is then challenged and has to adapt to that challenge. An inactive and leading a sedentary lifestyle is sort of the absence of challenge until things become too dysregulated.
Ben Miller:	29:02	We know that’s how a lot of the phytochemicals and botanicals work, these are very low dose stresses to the cell. As far as we know that’s one theory of how metformin is working, is it’s stimulating this low dose stress. Then there’s a lot of stuff with the fasting period and how long to fast and whether that triggers some of these stress responsiveness in the same way. I think those are all really interesting areas. There will probably be some common themes that emerge with these different treatments.
Dan Pardi:	29:31	It’s nice when that happens because you can see that there might be multiple ways to get at the core effect that we’re looking to do, whether it’s through plant phytochemicals, fasting exercise, and other sort of low dose hormetic stimulations. We see the induction of the survival pathways that support health. If we can do that through lifestyle, that’s probably better because like you said and exercise mimetic is an oversell. We know that exercise is doing so much to the body. The entire effect of exercise is not happening just at the electron transport chain, but for the vast majority of people who are increasingly so, are not living that healthy lifestyle. If there are these other pharmaceutical agents that have a lot of data behind them, that generally does reduce the progression from prediabetes to diabetes, reduces the risk for cancers and cardiovascular disease, like you I’m up for it as well. Our emphasis should always be on, can we do this by the way we live first and then when we can’t, then how do we do better?
Ben Miller:	30:24	Yeah, exactly.
Dan Pardi:	30:25	Are there other compounds that you’re looking at in your lab?
Ben Miller:	30:27	Yes. We’ve used some of the common, what you’d call hot area of slowed aging treatments. We have worked with rapamycin quite a bit, obviously not humans for rapamycin. We’ve worked with compounds that activate Nrf2, which is a transcription factor, which is known as the master regulator of the antioxidant response from the body. Those have been our primary, we’re beginning work with 17α-Estradiol, which is a non-feminizing estrogen, but that seems to work only in males and not females. So we’ve had our hands in a lot of these different treatments and caloric restriction. A lot of these are teaching us about the basic biology of aging. The Nrf2 activators aside, I don’t know if any of these are practical for human treatment, but these are things that we can learn from to potentially understand the basic biology of aging, so that we can then design more reasonable alternatives to some of these things that we know of, but might not be good for humans.
Dan Pardi:	31:26	I’m so interested in National Institution of Aging’s program, looking at the various compounds that have an impact. Rapamycin was top, that had the greatest effect. [inaudible 00:31:37] was second, and then things like 17α-Estradiol, methylene blue, couple of other compounds seemed to be quite interesting too. Do you know the mechanism for the 17α-Estradiol?
Ben Miller:	31:49	I do. So I’m working with someone that’s probably put more work into this compound than anybody else, and his name’s Mike Stout. He’s doing some great research and a lot of his data are indicating that these compounds, or the 17α-Estradiol is having an effect in the brain that regulates appetite pathways. So it’s probably having a metabolic effect.
Dan Pardi:	32:11	Are the compounds that you’re looking at as Nrf2 activators, are those natural compounds, or are those synthetic?
Ben Miller:	32:16	Yeah, so we work with a company that has designed the compounds based on synergism between multiple compounds that work well together to activate Nrf2. We did have one in the NIA program that you talked about, and that extended lifespan, a median lifespan in male mice, but not female mice but we have a second generation that’s in testing right now.
Dan Pardi:	32:38	Might that be commercialized in the future, or is this just a purely research endeavor?
Ben Miller:	32:42	The one that’s in testing right now is actually available commercially.
Dan Pardi:	32:46	It’s such an interesting subject and I can’t tell you how many questions, text messages I’ve gotten from colleagues and friends that are saying, “Hey, where do I get this stuff?” I’m looking at these mid-50 year old men who are very fit, who exercise regularly, who take care of themselves. What I appreciate about it is that they care very much to implement whatever’s cutting edge so that they can preserve their health span as long as possible. I’ve warned them against adopting metformin as a strategy to employ at the moment, because they’re not the population where this is shown to be beneficial.
Ben Miller:	33:17	Right, and if you consider exercise as a drug as well, and we know that there’s drug/drug interactions, I think that’s one worth considering that with these other treatments.
Dan Pardi:	33:26	Well, thank you so much for your time and coming on to join me on humanOS Radio today.
Ben Miller:	33:31	I appreciate it and I appreciate you highlighting the topic.
Speaker 2:	33:36	Thanks for listening and come visit us soon at humanos.me.

 

The post Does Metformin Block the Health Benefits of Exercise? Podcast with Ben Miller appeared first on humanOS.me.